Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Uterine Cervical Neoplasms 6Brenner Tumor 6Pancreatic Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Endometrial Adenocarcinoma 2Cervical Adenocarcinoma 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sertoli-Leydig Cell Tumor 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Rectal Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Penile Neoplasms 1Ovarian gynandroblastoma 1Neoplasms 1

Interventions

nirogacestat 1etoposide phosphate 1Taxes 1Platinum 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Disulfides × Gynecologic × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡